Hepion Pharmaceuticals is a biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Co.'s cyclophilin inhibitor, CRV431, is being developed to address these pathologies. CRV431 is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. CRV431 additionally shows in vitro antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease. We show 16 historical shares outstanding datapoints in our coverage of HEPA's shares outstanding history.
Understanding the changing numbers of HEPA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like HEPA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching HEPA by allowing them to research HEPA shares outstanding history
as well as any other stock in our coverage universe. |
Free HEPA Email Alerts:
Video: Shares Outstanding Importance
